FDA has removed certain bulk drug substances that were placed on the category two list and has announced it will consult the Pharmacy Compounding Advisory Committee (PCAC) for potential future inclusion of Injectable Peptides: Out of the Back Alley and Into the Light? Berkley Lifesciences FDA Proposes Exclusion of Semaglutide, Tirzepatide, Liraglutide from 503B Bulks List FDA posted on the topic LinkedIn Updated 2026 FDA Category 2 peptide list As the science and regulations continue to develop, it's important to work with providers who stay informed and prioritize safe, medically guided protocols. At Peptide Therapy in Austin, TX Austin Plastic Surgeon Dr. Chuma